<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474136</url>
  </required_header>
  <id_info>
    <org_study_id>DFC-PK-006</org_study_id>
    <nct_id>NCT00474136</nct_id>
  </id_info>
  <brief_title>Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium</brief_title>
  <official_title>Open-Label, Randomized, Single Center Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses) Versus Oral Diclofenac Potassium in Healthy Adult Volunteers Following Single- and Multiple-Dose Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javelin Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Javelin Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetic parameters of intravenous
      diclofenac sodium (DIC075V) 18.75 mg and 37.5 mg following single- and multiple-dose
      administration, as compared to oral diclofenac potassium (Cataflam® 50 mg), the approved
      reference product.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, three-treatment, six sequence, three-period, single center
      crossover study to evaluate the pharmacokinetics of intravenous diclofenac sodium DIC075V
      (18.75 mg and 37.5 mg) versus oral diclofenac potassium (Cataflam® 50 mg) in healthy adult
      volunteers following single- and multiple-dose administration. Each treatment sequence
      received 1 dose every 6 hours (for a total of 4 doses per treatment sequence) with a 48-hour
      washout period between treatment sequences.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the pharmacokinetic parameters of intravenous diclofenac sodium (DIC075V) 18.75 mg and 37.5 mg following single- and multiple-dose administration, as compared to oral diclofenac potassium (Cataflam® 50 mg), the approved reference product.</measure>
    <time_frame>Several time points over 7 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous diclofenac sodium (DIC075V) 18.75 mg</intervention_name>
    <description>DIC075V 18.75 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous diclofenac sodium (DIC075V) 37.5 mg</intervention_name>
    <description>DIC075V 37.5 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral diclofenac potassium 50 mg</intervention_name>
    <description>Oral diclofenac potassium 50 mg</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Cataflam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers between 18 and 55 years of age.

        Exclusion Criteria:

          -  Smoked or used tobacco or nicotine products in the past six months or expects to
             during the study.

          -  Known allergy or hypersensitivity to diclofenac, aspirin, or other NSAIDs.

          -  History of previous and/or present peptic ulceration, GI bleeding or any bleeding
             diathesis, positive for hepatitis B or hepatitis C or for HIV antibodies, or history
             of asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terri Lunsford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL International</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2007</study_first_posted>
  <last_update_submitted>December 27, 2007</last_update_submitted>
  <last_update_submitted_qc>December 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Amy Cohen</name_title>
    <organization>Javelin Pharmaceuticals</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

